Public Policy Priorities

Print Friendly



For 25 years, Celiac Disease Foundation and our national network of activists have worked diligently for federal recognition of celiac disease as one of the world’s most prevalent, and least diagnosed, genetic autoimmune diseases.  We continue to educate our elected officials on the need for funding of celiac disease research and education programs, and gluten-free labeling standards, and to demonstrate the impact of celiac disease on individuals and their families.  Together, we must work to make our voices heard to elevate celiac disease on the nation’s health care agenda.  CDF is committed to working with the United States Congress, federal government agencies and state legislatures and agencies to improve the lives of the more than 3 million Americans affected by celiac disease.

  • Passage of H.R. 3648: Gluten in Medication Disclosure Act of 2015:  In 2012, Representatives Tim Ryan (OH-13) and Nita Lowey (NY-17) introduced legislation that would require gluten disclosure in medications, both prescription and over-the-counter. We strongly endorsed this legislation when it was first introduced in 2012, but it never made it to a vote. Fortunately, Representatives Ryan and Lowey have reintroduced this legislation. Celiac Disease Foundation is proud to endorse the Gluten in Medicine Disclosure Act of 2015, and we pledge our support to get this important legislation through Congress this year. Read the press release here.
    “Help spread the word! Click here to view a sample ‘Letter to the Editor'”
  • Passage of the 21st Century Cures Act: In a rare moment of bipartisan cooperation in Washington, D.C., the landmark 21st Century Cures legislation passed the U.S. House in early July, 2015, by a vote of 344-77. The bill, co-authored by Republican Fred Upton and Democrat Diana DeGette, seeks to bring new drugs and treatments to market faster by encouraging medical innovation in research, and streamlining some FDA requirements. It also includes almost $9 billion in new funding for NIH for research, and more than $500 million in new funding for the FDA to implement structural changes in the review of medical treatments. This legislation is far from perfect, however. We acknowledge the real concerns of public health specialists who believe that the legislation will weaken safety reviews, especially of medical devices. But we cannot let perfection be the enemy of the good. Celiac Disease Foundation urges you to contact your Senator and demand that the Senate take up and pass this critical bipartisan legislation during the fall session
    “Help spread the word! Click here to view a sample ‘Letter to the Editor”
  • Continued and expanded application of the FDA Gluten-Free Labeling Rule: In August 2014, the Food and Drug Administration required that all foods labeled gluten-free must contain less than 20 parts per million of gluten. This ruling, 10 years in the making, was a great victory to the gluten-free community, allowing consumers to buy gluten-free products with confidence. One of the first disease advocacy organizations to advocate for gluten-free labeling standards, Celiac Disease Foundation continues to work with the FDA to ensure this rule is upheld, and to clarify its application to food service establishments, as well as medications and supplements.
  • Recognition by the National Institutes of Health for federal research grants: Research is limited by the amount of funding provided. Federal research grants will give celiac disease researchers the funding they need to make great strides in advancing treatment, driving diagnosis, managing symptoms, and finding a cure for celiac disease.